Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 4/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | DAO | P14920 | 1/20 | 0.56 |
| ▸ | RNASEH1 | O60930 | 2/20 | 0.55 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18248 | 0.89 | PNP (1.00) | PNPKMT2A | |
| SCHEMBL8695702 | 0.89 | PNP (0.70) | PNPKMT2ADAORNASEH1HTR2C | |
| SCHEMBL3425171 | 0.85 | PNP (0.69) | PNPKMT2ADAORNASEH1 | |
| SCHEMBL1533590 | 0.85 | PNP (0.65) | PNPKMT2ADAORNASEH1HTR2C | |
| SCHEMBL1533532 | 0.85 | PNP (0.65) | PNPKMT2ADAORNASEH1HTR2C | |
| SCHEMBL3433598 | 0.84 | PNP (0.68) | PNPKMT2APKM | |
| SCHEMBL2776925 | 0.83 | PNP (0.66) | PNPKMT2ADAORNASEH1 | |
| SCHEMBL2788675 | 0.83 | PNP (0.66) | PNPKMT2ADAORNASEH1RXFP1 | |
| SCHEMBL5084818 | 0.83 | PNP (0.58) | PNPKMT2ADAORNASEH1 | |
| SCHEMBL10988912 | 0.82 | PNP (0.61) | PNPKMT2ADAORNASEH1HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1670809-B1 | SYNTHESIS AND MANUFACTURE OF PENTOSTATIN AND ITS PRECURSORS, ANALOGS AND DERIVATIVES | MAYNE PHARMA PLC (GB) | 2016-01-13 | — | — | EP | disclosed |
| EP-1670809-A2 | SYNTHESIS AND MANUFACTURE OF PENTOSTATIN AND ITS PRECURSORS, ANALOGS AND DERIVATIVES | SuperGen, Inc. (US) | 2006-06-21 | — | — | EP | disclosed |
| US-20050267056-A1 | Synthesis and manufacture of pentostatin and its precursors, analogs and derivatives | MAYNE PHARMA (USA) INC. | 2005-12-01 | — | — | US | disclosed |
| WO-2005027838-A2 | SYNTHESIS AND MANUFACTURE OF PENTOSTATIN AND ITS PRECURSORS, ANALOGS AND DERIVATIVES | SUPERGEN, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267056-A1 | Synthesis and manufacture of pentostatin and its precursors, analogs and derivatives | UMPS, THPO, DHPS | PNP 31/4885KMT2A 2391/4885DAO 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.